Journal of Infection and Chemotherapy最新文献

{"title":"Vaccination strategies for transplantation in Japan (solid organ transplantation and hematopoietic stem cell transplantation)","authors":"Takeshi Tanaka ,&nbsp;Satoshi Kakiuchi ,&nbsp;Ayumi Fujita ,&nbsp;Masato Tashiro ,&nbsp;Koichi Izumikawa","doi":"10.1016/j.jiac.2025.102772","DOIUrl":"10.1016/j.jiac.2025.102772","url":null,"abstract":"<div><div>The management of infectious diseases in immunocompromised patients represents a critical component of managing severe and refractory conditions, with early diagnosis and prompt therapeutic intervention serving as fundamental principles. Vaccine-preventable disease (VPD) management is equally essential. From a health economics perspective, this approach is pivotal in preventing potentially intractable scenarios. This article reviews immunization strategies in adult patients undergoing solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) in Japan, two distinct categories of immunocompromised individuals. Although many recommended vaccines overlap between these groups, the timing and significance of vaccination prophylaxis differ. Patients who undergo SOT remain immunocompromised long-term, whereas those who have received HSCT experience a period of immune reconstitution following the cessation of immunosuppressive therapy. Additionally, numerous recommended vaccinations must be completed within a defined timeframe, and their management is more complex than that for immunocompetent individuals. Recently, several new vaccines, such as those for Severe.</div><div>Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), recombinant zoster, pneumococcal (Pneumococcal conjugate vaccine (PCV)15, 20, 21), and Respiratory syncytial virus (RSV), have been introduced. Recommended vaccination guidance varies across countries, combining established and new information, although some updates may not yet be incorporated. This article provides an overview of current vaccination guidance for SOT and HSCT recipients, highlighting country-specific issues in Japan as well as common challenges faced globally, and proposes optimal strategies for future vaccination policies in Japan.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 9","pages":"Article 102772"},"PeriodicalIF":1.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Capnocytophaga sputigena bacteremia in a patient with acute lymphoblastic leukemia.","authors":"Haruki Naruse, Tomoya Maeda, Noriyuki Watanabe, Mieko Tokano, Sachie Koyama, Sachi Tanaka, Yoshitada Taji, Norihito Tarumoto, Naoki Takahashi, Kotaro Mitsutake, Yasuhiro Ebihara","doi":"10.1016/j.jiac.2025.102771","DOIUrl":"https://doi.org/10.1016/j.jiac.2025.102771","url":null,"abstract":"<p><p>Capnocytophaga sputigena, a species of bacteria resident in the human oral cavity, can rarely cause opportunistic infections in immunocompromised patients. The present case concerns a 40-year-old man with acute lymphoblastic leukemia, diagnosed in 2001, who underwent two hematopoietic stem cell transplants and had experienced relapses and remissions over nearly a 20-year period. Because his acute lymphoblastic leukemia was refractory, he was no longer receiving active treatment and was instead managed with supportive care. Under these circumstances, he developed febrile neutropenia with stomatitis, and C. sputigena was detected in blood culture. Cefepime was ineffective, but the patient's symptoms improved with tazobactam/piperacillin. The isolate was found to harbor the resistance genes Capnocytophaga sputigena β-lactamase-1 (CSP-1), cfxA3, and erm(F). The simultaneous presence of both CSP-1 and cfxA3 genes is rare. Since standard drug susceptibility testing forC. sputigenahas not yet been established, it is important to establish a standard drug susceptibility test for the appropriate treatment of C. sputigena. And physicians should consider the possibility that C. sputigena may be the causative microorganism in febrile neutropenia associated with oral mucosal injury.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102771"},"PeriodicalIF":1.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A feasibility study for personalized phage therapy against drug-resistant bacteria in Japan.","authors":"Kayoko Hayakawa, Kotaro Kiga, Shinjiro Ojima, Kotaro Chihara, Azumi Tamura, Wakana Yamashita, Tomohiro Nakamura, Aa Haeruman Azam, Wenhan Nie, Yuta Sato, Jun Sakai, Kohei Kondo, Yoshimasa Takahashi, Koichi Watashi, Sho Saito, Yuki Moriyama, Masami Kurokawa, Kazuhisa Mezaki, Hirotake Ohashi, Yasukata Ohashi, Takahiro Nishimura, Koh Shinohara, Yoshiaki Yamagishi, Yohei Doi, Norio Ohmagari","doi":"10.1016/j.jiac.2025.102770","DOIUrl":"https://doi.org/10.1016/j.jiac.2025.102770","url":null,"abstract":"<p><strong>Introduction: </strong>Personalized phage therapy is used in Europe and the United States to treat intractable infections caused by drug-resistant bacteria. This pilot study aimed to acquire feasibility data for clinical trials of individualized phage therapy in Japan.</p><p><strong>Methods: </strong>An observational study was conducted from August 2023 to September 2024 in adults with drug-resistant bacterial infections and treatment failure or recurrence/relapse following antimicrobial therapy. Phages with activity against the detected bacteria were then identified from the environment and an existing phage library.</p><p><strong>Results: </strong>Thirty patients with drug-resistant bacterial infections were enrolled. Of these, six (20%) died within 30 days of detection. The most commonly detected bacteria were methicillin-resistant Staphylococcus aureus (MRSA) (n=10, 33.3%) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) (n=5, 16.7%). The most common nontuberculous mycobacterium (NTM) was Mycobacterium avium (n=4, 13.3%), followed by Mycobacterium abscessus (n=2, 6.7%). In terms of infection types, respiratory tract infections were the most common (n=13, 43.3%), followed by bone and joint infections (n=6, 20%) and skin and soft tissue infections (n=6, 20%). Phages with a titer of 10⁸ PFU/ml or higher could be prepared for 26 out of 30 strains (86.7%). Phages against CRPA were more readily identified from the environment than for MRSA and NTM. A phage against CRPA was purified to a lipopolysaccharide concentration of 0.023 EU/10⁸ PFU.</p><p><strong>Conclusion: </strong>Personalized phages can be prepared for intractable infections caused by drug-resistant bacteria. These results support clinical trials to implement personalized phage therapy in Japan.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102770"},"PeriodicalIF":1.9,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical intracerebral hemorrhage and internal jugular vein thrombosis in meningovascular neurosyphilis","authors":"Motohiro Okumura ,&nbsp;Kenichi Sakuta ,&nbsp;Taku Gomi ,&nbsp;Yuya Yamaguchi ,&nbsp;Hideyuki Shimizu ,&nbsp;Satoshi Matsushima ,&nbsp;Yasuyuki Iguchi","doi":"10.1016/j.jiac.2025.102769","DOIUrl":"10.1016/j.jiac.2025.102769","url":null,"abstract":"<div><div>A previously healthy 63-year-old man presented with sudden-onset headache and left-sided clumsiness. Computed tomography revealed a linear hematoma extending from the cerebellar vermis to the left cerebellar hemisphere. Brain magnetic resonance imaging revealed an incidental thrombus occlusion of the left internal jugular vein. Based on his history of unprotected sexual intercourse, mild cognitive impairment, laboratory findings, and cerebrospinal fluid tests, he was diagnosed with meningovascular neurosyphilis. Treatment with intravenous penicillin G resulted in the resolution of both hemorrhage and venous thrombosis, emphasizing the need to consider meningovascular neurosyphilis as a differential diagnosis for unexplained hemorrhagic stroke.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102769"},"PeriodicalIF":1.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of acute myeloid leukemia with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis successfully treated by cord blood transplantation","authors":"Natsumi Yoda ,&nbsp;Takafumi Tsushima ,&nbsp;Chiharu Kimeda ,&nbsp;Kazusuke Tanaka ,&nbsp;Kosuke Matsuo ,&nbsp;Rena Matsumoto ,&nbsp;Sonoko Shimoji ,&nbsp;Yoshikazu Utsu ,&nbsp;Shin-Ichi Masuda ,&nbsp;Ken-Ichi Imadome ,&nbsp;Nobuyuki Aotsuka","doi":"10.1016/j.jiac.2025.102767","DOIUrl":"10.1016/j.jiac.2025.102767","url":null,"abstract":"<div><div>Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory life-threatening syndrome. Epstein-Barr virus (EBV) infection is a common cause of HLH. Occasionally, HLH develops with malignancies such as lymphoma. Concurrent cases of acute myeloid leukemia (AML) and EBV-associated HLH (EBV-HLH) are very rare, and the treatment has not been established. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for refractory HLH and high-risk AML. Consequently, HSCT would be a good treatment for cases of HLH and high-risk AML coexistence. A 66-year-old man was diagnosed with high-risk AML. After induction chemotherapy, he experienced prolonged pancytopenia, high fever, and elevated liver enzymes. A high EBV viral load was found, and he was diagnosed with EBV-HLH, with EBV infecting CD8⁺ T-cells. EBV-HLH was resolved by treatment with corticosteroids. Meanwhile, some hemophagocytosis remained after consolidation chemotherapy, and EBV-DNA in whole blood was positive. The patient received cord blood transplantation to treat both AML and EBV-HLH. His AML achieved complete remission, and the hemophagocytosis was in remission. However, his EBV viral load increased again 53 days after transplantation. Then, the EBV infection occurred in B-cells, and there was no relapse of hemophagocytosis. In conclusion, both AML and HLH were successfully treated by transplantation. This report highlights treatment strategies in specific cases of AML and EBV-HLH coexistence.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102767"},"PeriodicalIF":1.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV-associated neurocognitive dysfunction in the Chugoku-Shikoku region of Japan: A cross-sectional study","authors":"Hisafumi Kihara ,&nbsp;Aya Nakao ,&nbsp;Tatsuya Konishi ,&nbsp;Jun Yamanouchi ,&nbsp;Takumi Nishida ,&nbsp;Miho Nakamura ,&nbsp;Seisho Takeuchi ,&nbsp;Yutaka Sato ,&nbsp;Yumi Akamatsu ,&nbsp;Hidetoshi Tani ,&nbsp;Hideho Wada ,&nbsp;Emi Tokui ,&nbsp;Michiko Kawata ,&nbsp;Takashi Kaimen ,&nbsp;Shuji Ozaki ,&nbsp;Chie Iketani ,&nbsp;Kentaro Kawabe ,&nbsp;Kiyonori Takada","doi":"10.1016/j.jiac.2025.102768","DOIUrl":"10.1016/j.jiac.2025.102768","url":null,"abstract":"<div><h3>Introduction</h3><div>Although combination antiretroviral therapy (cART) is widely used, HIV-associated neurocognitive disorder (HAND) remains a significant challenge for people living with HIV. This study aimed to investigate the characteristics of HAND among HIV patients in the Chugoku-Shikoku region of Japan using the CoCoBattery, a unified neurocognitive test employed in a nationwide multicenter prospective cross-sectional study on HAND.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted in seven general hospitals from January 2019 to March 2023, including 103 HIV patients. HAND was classified into HIV-associated dementia (HAD), mild neurocognitive disorder (MND), and asymptomatic neurocognitive impairment (ANI, asymptomatic HAND) based on the Frascati criteria. Multivariable logistic regression analysis was performed to identify factors associated with HAND and asymptomatic HAND.</div></div><div><h3>Results</h3><div>Among the 103 patients, 62 (60.2 %) were diagnosed with HAND, including 11 (10.7 %) with HAD, 16 (15.5 %) with MND, and 35 (34.0 %) with ANI. No significant differences in baseline characteristics were observed between the HAND and non-HAND groups. However, a positive association was observed between an HIV-RNA copy number ≥200 copies/mL and asymptomatic HAND (adjusted odds ratio (OR): 11.15; 95 % confidence interval (CI): 1.13–297.17). Notably, 10 ANI patients exhibited neurocognitive impairment equivalent to HAD.</div></div><div><h3>Conclusions</h3><div>ANI accounted for a large proportion of HAND cases and included patients with significant neurocognitive impairment. Elevated HIV-RNA copy numbers were associated with ANI, highlighting the need for careful monitoring and support for these patients, even in the absence of subjective symptoms.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102768"},"PeriodicalIF":1.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin–bilirubin (ALBI) score of patients with liver dysfunction","authors":"Shunsuke Nashimoto ,&nbsp;Mitsuru Sugawara ,&nbsp;Yoh Takekuma","doi":"10.1016/j.jiac.2025.102766","DOIUrl":"10.1016/j.jiac.2025.102766","url":null,"abstract":"<div><h3>Introduction</h3><div>Voriconazole (VRCZ) is an antifungal agent used to treat refractory fungal infections. Its dosage is adjusted based on the individual liver function. In this study, we aimed to establish a population pharmacokinetic analysis model based on the albumin–bilirubin (ALBI) score to objectively assess the liver function using only albumin and total bilirubin levels as covariates.</div></div><div><h3>Methods</h3><div>In total, 126 plasma samples of 16 patients with liver dysfunction who received oral VRCZ between 2012 and 2022 were analyzed in this study. Phoenix NLME software was used for population pharmacokinetic analysis, and Monte Carlo simulations were performed to determine the optimal dosing regimen to achieve the target blood VRCZ concentration.</div></div><div><h3>Results</h3><div>Blood VRCZ concentration was described using a one-compartment model with lag time. In the final model, objective function was significantly decreased upon ALBI score incorporation into clearance. Monte Carlo simulations showed that the optimal dosing schedules were 100 mg twice daily, 75 mg twice daily, and 50 mg twice daily for ALBI scores of −3, −2, and −1, respectively. Notably, for an ALBI score of 0, target blood VRCZ concentration was exceeded, even a dosing regimen of 50 mg twice daily.</div></div><div><h3>Conclusion</h3><div>To the best of our knowledge, this study is the first to incorporate the ALBI score into a population pharmacokinetic model for VRCZ. Our simulation results suggest that the maintenance dose should be reduced based on the ALBI score. Furthermore, our findings highlight the potential use of the ALBI score for optimal drug dosage design.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102766"},"PeriodicalIF":1.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the GeneSoC rapid quantitative PCR system for Treponema pallidum detection","authors":"Hitomi Mizushina ,&nbsp;Kazuo Imai ,&nbsp;Yuki Ohama ,&nbsp;Akihiro Sato ,&nbsp;Masashi Tanaka ,&nbsp;Ryuha Omachi ,&nbsp;Keita Takeuchi ,&nbsp;Shu-ichi Nakayama ,&nbsp;Yukihiro Akeda ,&nbsp;Takuya Maeda","doi":"10.1016/j.jiac.2025.102765","DOIUrl":"10.1016/j.jiac.2025.102765","url":null,"abstract":"<div><div>The incidence of syphilis, caused by <em>Treponema pallidum</em> (TP), is increasing worldwide. Nucleic acid amplification tests, including quantitative PCR (qPCR), are valuable for diagnosing primary syphilis, particularly using ulcer/lesion swabs. Recent studies have also shown the promising diagnostic performance of nucleic acid amplification tests using saliva. The GeneSoC platform, a rapid qPCR system capable of completing 50 PCR cycles in 15 min, has been used for the diagnosis of infectious diseases, but has not been assessed for syphilis. This study aimed to evaluate the performance of the GeneSoC rapid qPCR assay for TP detection in clinical samples. We evaluated clinical specimens from ulcer/lesion swabs (syphilis, <em>n</em> = 43; non-syphilis, <em>n</em> = 20) and saliva (syphilis, <em>n</em> = 33; non-syphilis, <em>n</em> = 20). All syphilis samples were confirmed to be positive by conventional qPCR and stored before analysis with the GeneSoC rapid qPCR assay. The GeneSoC rapid qPCR assay had a detection limit for TP DNA of 20 copies/reaction, compared with 2 copies for the conventional qPCR assay. The results for the GeneSoC and conventional qPCR assays showed 100 % concordance for ulcer/lesion swabs. For saliva samples, the positive agreement rate was lower with crude DNA (63.6 %) but improved with purified DNA (84.8 %). The negative agreement rate was 100 % for both sample types. The GeneSoC rapid qPCR assay is a promising point-of-care test for primary syphilis using ulcer/lesion swabs. However, further optimization and validation, especially for saliva, are needed for its broader clinical use.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102765"},"PeriodicalIF":1.9,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of booster vaccination on post-treatment oxygen deterioration in hospitalized mild-to-moderate COVID-19 Japanese patients with comorbidities during the Omicron wave","authors":"Shunsaku Hayai ,&nbsp;Kensuke Fukumitsu ,&nbsp;Atsushi Suzuki ,&nbsp;Jun Fukihara ,&nbsp;Takuma Katano ,&nbsp;Toshiyuki Yonezawa ,&nbsp;Tomoyuki Ogisu ,&nbsp;Hiroyuki Tanaka ,&nbsp;Takahiro Inoue ,&nbsp;Hisashi Kako ,&nbsp;Yuri Maeda ,&nbsp;Makoto Ishii ,&nbsp;Akio Niimi ,&nbsp;Kazuyoshi Imaizumi ,&nbsp;Etsuro Yamaguchi","doi":"10.1016/j.jiac.2025.102764","DOIUrl":"10.1016/j.jiac.2025.102764","url":null,"abstract":"<div><h3>Introduction</h3><div>Although the emergence of the Omicron variant has decreased overall mortality from Coronavirus Disease 2019 (COVID-19) compared to the Delta variant, elderly individuals with comorbidities remain at increased risk of adverse outcomes. While vaccination and antiviral treatments have reduced the severity of COVID-19, data on the impact of booster vaccination on post-hospitalization oxygen deterioration in the Japanese population remain limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study of hospitalized mild-to-moderate COVID-19 Japanese patients during the Omicron variant wave (December 2021 to October 2022). Both vaccinated and unvaccinated patients were included and categorized into three groups based on their vaccination status: unvaccinated (0–1 vaccine dose), primary series (2 vaccine doses), and booster group (3–4 vaccine doses). Demographic and clinical data were collected, and the frequency and time to post-hospitalization oxygen deterioration were evaluated among the three groups.</div></div><div><h3>Results</h3><div>A total of 596 patients were analyzed (141 unvaccinated, 180 primary series, and 275 booster group). The booster group showed significantly lower rates of oxygen deterioration and a longer time to deterioration compared to the other groups, despite being older and having more comorbidities. A multivariate analysis, adjusted for age and gender, revealed that booster vaccination was significantly associated with a reduced risk of oxygen deterioration after initial treatment. Similar results were observed in the subgroup analysis of elderly patients aged 65 years and older.</div></div><div><h3>Conclusion</h3><div>Our study demonstrated the effectiveness of booster vaccination on preventing post-treatment oxygen deterioration in hospitalized mild-to-moderate COVID-19 Japanese patients with comorbidities during the Omicron wave.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102764"},"PeriodicalIF":1.9,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe drug eruption induced by teicoplanin, complicated by hemophagocytic syndrome: A case report and brief literature review","authors":"Hiroyuki Kato,&nbsp;Tsuyoshi Kitaura,&nbsp;Syotaro Ishihara,&nbsp;Ryota Amitani,&nbsp;Kyosuke Nagamizu,&nbsp;Kensaku Okada,&nbsp;Masaki Nakamoto,&nbsp;Hiroki Chikumi","doi":"10.1016/j.jiac.2025.102763","DOIUrl":"10.1016/j.jiac.2025.102763","url":null,"abstract":"<div><div>A 67-year-old male was treated with ampicillin for infective endocarditis and lumbar pyogenic spondylitis caused by <em>Enterococcus fecalis</em>. The patient was switched to the antibacterial drug teicoplanin because of ampicillin-induced tubulointerstitial nephritis, and fever and skin rash were observed on the eighth day after the drug change. The fever and skin rash gradually resolved; however, hepatotoxicity and thrombocytopenia were observed subsequently. Owing to elevated ferritin and sIL-2R levels, a bone marrow puncture was performed, revealing hemophagocytosis, leading to a diagnosis of hemophagocytic syndrome. Although teicoplanin-induced hemophagocytic syndrome has not been previously reported and is considered rare, clinicians should be aware of its adverse effects, particularly when a severe drug eruption is accompanied by thrombocytopenia.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102763"},"PeriodicalIF":1.9,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}